Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$536.2M+9.3%$490.73M+12.6%$435.83M+30.5%$333.87M+22.1%$273.53M+17.3%
$7.61M-26.4%$10.34M0.0%$10.34M-0.4%$10.38M-4.9%$10.92M+41.0%
$528.59M+10.0%$480.39M+12.9%$425.49M+31.5%$323.49M+23.2%$262.61M+16.5%
98.6%+0.7pp97.9%+0.3pp97.6%+0.7pp96.9%+0.9pp96%-0.7pp
$216.22M+5.0%$206.01M-2.0%$210.21M+0.1%$210M-2.3%$214.97M-1.2%
$344.62M+6.1%$324.78M+11.0%$292.58M+7.7%$271.75M+4.4%$260.31M-1.4%
$593.26M+7.2%$553.55M+5.0%$526.96M+4.1%$506.08M+1.1%$500.8M-10.1%
-$57.06M+9.2%-$62.82M+31.1%-$91.13M+47.1%-$172.21M+24.2%-$227.26M+29.8%
-10.6%+2.2pp-12.8%+8.1pp-20.9%+30.7pp-51.6%+31.5pp-83.1%+55.8pp
$10.19M-5.2%$10.75M-4.6%$11.27M-0.2%$11.3M+0.5%$11.24M+0.5%
$12.25M-9.6%$13.55M+425%$2.58M-17.0%$3.11M+133%$1.33M-59.8%
-$44.81M+9.1%-$49.27M+44.4%-$88.55M+47.6%-$169.1M+25.2%-$225.93M+29.5%
$829K-16.1%$988K
-$88.54M+47.6%-$169.06M+25.4%-$226.71M+29.5%
-$1.04+48.5%-$2.02+27.6%-$2.79+31.6%
$16.09M+874%-$2.08M+94.3%-$36.43M+70.2%-$122.06M+32.5%-$180.79M+35.5%
3%+3.4pp-0.4%+7.9pp-8.4%+28.2pp-36.6%+29.5pp-66.1%+54.1pp
-$57.06M+9.2%-$62.82M+31.1%-$91.13M+47.1%-$172.21M+24.2%-$227.26M+29.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Travere Therapeutics, Inc.'s profit margins?
Gross margin is 98.6% and operating margin is -10.6%, with a -20.3% net margin.
Where does Travere Therapeutics, Inc.'s income statement data come from?
Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.